Perrigo (NYSE:PRGO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Perrigo (NYSE:PRGO) from a hold rating to a buy rating in a report published on Saturday.

Other equities analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Price Performance

PRGO stock opened at $12.69 on Friday. Perrigo has a one year low of $9.23 and a one year high of $24.60. The firm has a 50-day moving average of $10.66 and a two-hundred day moving average of $11.49. The firm has a market capitalization of $1.76 billion, a PE ratio of -1.01, a P/E/G ratio of 1.46 and a beta of 0.51. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31.

Perrigo (NYSE:PRGO) last released its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the firm posted ($0.06) earnings per share. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, analysts forecast that Perrigo will post 2.2 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be issued a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 9.1%. The ex-dividend date is Friday, August 28th. Perrigo’s dividend payout ratio (DPR) is currently -9.27%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amundi boosted its stake in shares of Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after buying an additional 556 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Perrigo by 126.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares in the last quarter. United Services Automobile Association acquired a new position in shares of Perrigo in the first quarter worth $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Perrigo by 6.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after acquiring an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.